奥沙利铂联合卡培他滨治疗晚期胃癌临床观察

目的观察奥沙利铂联合卡培他滨治疗晚期胃癌的临床疗效和不良反应。方法奥沙利铂130mg/m2,加入5%的葡萄糖注射液500ml中静脉滴注3h,第1天;卡培他滨1000mg/m2,2次/d,第1~14天,21d为一周期,所有患者均接受至少2个周期的化疗。结果28例患者入组,均可行疗效及不良反应评价,其中完全缓解0例,部分缓解12例,总有效率42.8%。主要不良反应为骨髓毒性、外周神经毒性及手足综合症,均相对较轻。结论奥沙利铂联合卡培他滨方案治疗晚期胃癌有较好的疗效,毒副反应小,值得临床进一步研究。

Clinical Observation of Oxaliplatin Combined with Capecitabine for Advanced Gastric Cancer

Objective To investigate the efficacy and toxicity of Oxaliplatin combined with Capeeitabine in treating advanced gastric cancer. Methods Oxaliplatin（ 130 mg/m2, intravenous infusion on day 1 for three hours） and Capecitabine （1000 mg/ m2 , per oral, twice daily for 14 days） were administered in a 21 days treatment course. All patients received at least two courses of treatment. Results Twenty-eight patients were enrolled in this study. All patients were included in the efficacy and adverse e- vents analysis. There were no complete responses, twelve partial responses, giving an overall response rate of 42.8%. The major toxicity included myelotoxicity, peripheral neurotoxieity and hand-foot syndrome, all were generally mild. Conclusions Oxalipla- tin combined with Capecitabine demonstrates clinical activity and an acceptable safety profile in patients with advanced gastric cancer. Clearly further investigation is warranted as we work.